EU approves first-line use of AZ’ Tagrisso in lung cancer
admin 11th June 2018 Uncategorised 0AstraZeneca’s Tagrisso has been given a green light in Europe for first-line use to treat EGFR-mutated non-small cell lung cancer (NSCLC), offering a new line of attack at this stage of the disease.
More: EU approves first-line use of AZ’ Tagrisso in lung cancer
Source: News